Earlier studies evaluating exclusively ovarian cancer patients found a frequency of 11 to 15% germline pathogenic variants in BRCA1 or BRCA2 among epithelial ovarian cancer patients [10–15]. This evidence concerns the gene BRCA1 and ovarian cancer.